Double-edged sword?

JAMA Internal Medicine

Volumn 173, Issue 13, 2013, Pages 1184-1185

  Woodruff, Prescott G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE;

ASTHMA; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; HEART INFARCTION; HOSPITALIZATION; HUMAN; INHALER; LUNG FUNCTION; MORTALITY; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE;

BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84879996035     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.1201     Document Type: Note

References (10)

1. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease [published online May 20, 2013]. JAMA Intern Med. 2013;173(13):1175-1184.
2. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
3. Tashkin DP, Celli B, Senn S, et al UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
4. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
5. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215. doi:10.1136/bmj.d3215.
6. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax. 2013;68(1):48-56.
7. Wise RA, Anzueto A, Calverley P, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR): a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40. doi:10.1186/1465-9921-14-40.
8. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol [published correction appears in Chest. 2006;129(5):1393]. Chest. 2006;129(1):15-26. (Pubitemid 43265239)
9. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: ameta-analysis. Chest. 2004;125(6):2309-2321. (Pubitemid 38796452)
10. Calverley PM, Anderson JA, Celli B, et al TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719-725.